Value of serum leucine-rich alpha-2 glycoprotein in evaluating the disease activity of small bowel Crohn′s disease
10.3760/cma.j.cn101480-20231028-00041
- VernacularTitle:血清富亮氨酸α-2糖蛋白在评估小肠克罗恩病疾病活动度中的价值
- Author:
Yalong ZHU
1
;
Jingyi HUANG
1
;
Yue LI
1
Author Information
1. 中国医学科学院 北京协和医学院 北京协和医院消化内科，北京 100730
- Publication Type:Journal Article
- Keywords:
Small bowel Crohn′s disease;
Leucine-rich alpha-2 glycoprotein;
Biomarker;
Disease activity
- From:
Chinese Journal of Inflammatory Bowel Diseases
2024;08(3):238-241
- CountryChina
- Language:Chinese
-
Abstract:
Small bowel Crohn′s disease (CD) has a hidden onset, with a high risk of complications such as intestinal stenosis and fistulas, and a poor prognosis. Currently, there is still no ideal biomarker for clinical assessment of disease activity in small bowel CD, and there is a lack of non-invasive biomarkers that can sensitively reflect the activity of small bowel CD. Studies have found that the serum level of leucine-rich alpha-2 glycoprotein (LRG) is positively correlated with the disease activity of small bowel CD. This article reviews the relevant research of LRG in evaluating the small bowel CD and looks into its potential application prospects.
